Valuation: Palvella Therapeutics, Inc.

Market Cap 2.03B 1.79B 1.66B 1.53B 2.87B 195B 2.91B 19.78B 7.72B 96.29B 7.63B 7.47B 333B P/E 2026 *
-24.9x
P/E 2027 * -20.1x
Enterprise Value 1.84B 1.61B 1.5B 1.38B 2.59B 176B 2.62B 17.86B 6.97B 86.93B 6.89B 6.74B 300B EV / Sales 2026 *
-
EV / Sales 2027 * 66.6x
Free-Float
88.35%
Yield 2026 *
-
Yield 2027 * -
1 day+2.72%
1 week+14.19%
Current month-7.23%
1 month-4.35%
3 months+10.21%
6 months+68.83%
Current year+35.44%
1 week 136.68
Extreme 136.68
146.15
1 month 120.61
Extreme 120.6053
161.38
Current year 72.22
Extreme 72.225
161.38
1 year 34.57
Extreme 34.57
161.38
3 years 11.17
Extreme 11.17
161.38
5 years 11.17
Extreme 11.17
161.38
10 years 11.17
Extreme 11.17
161.38
Date Insider Type Main position Quantity % Market Cap.
7/15/26 Fiscal year

Chief Operating Officer

12,906 0.0900%
6/29/26 Free

Director

6,000 0.0418%
6/17/26 Fiscal year

Chief Operating Officer

12,906 0.0900%
Change 5-day change 1-year change 3-year change Capi.($)
+2.72%+14.19%+267.09% - 2.03B
-0.38%+3.50%+53.73%+73.30% 56.19B
-0.27%+0.35%+40.26%+79.88% 54.83B
+1.97%-1.16%-21.00%-13.25% 23.04B
-2.05%-2.14%+0.75%+413.38% 22.7B
-0.21%-0.62%+20.56%-10.90% 20.23B
-1.28%+1.65%+25.74%-30.44% 17.83B
-0.97%-0.59%+33.12%+550.67% 15.65B
+5.29%+1.70%+185.09%+333.94% 15.24B
+0.79%+0.50%+22.39%+184.74% 14.03B
Average +0.56%+2.21%+62.77%+175.70% 24.18B
Weighted average by Cap. +0.07%+1.18%+40.66%+138.13%

Financials

2026 *2027 *
Net sales - 30.55M 26.86M 25M 22.96M 43.11M 2.93B 43.68M 297M 116M 1.45B 115M 112M 5B
Net income -79.08M -69.52M -64.71M -59.43M -112M -7.58B -113M -769M -300M -3.74B -297M -290M -12.94B -119M -104M -97.02M -89.1M -167M -11.37B -170M -1.15B -450M -5.61B -445M -435M -19.4B
Net Debt -198M -174M -162M -149M -279M -18.95B -283M -1.92B -751M -9.36B -742M -726M -32.34B -
Logo Palvella Therapeutics, Inc.
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. The Company is developing a pipeline of product candidates based on its patented QTORIN platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Its QTORIN product candidates are developed to accommodate the cargo at high concentrations in order to drive sufficient drug to its target deep in the epidermis and dermis. The Company's lead product candidate, QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin), is being evaluated in the Phase III SELVA clinical trial in microcystic lymphatic malformations and the Phase II TOIVA clinical trial in cutaneous venous malformations.
Employees
29
Date Price Change Volume
26-07-27 US$141.77 +2.72% 173,587
26-07-24 US$138.01 -3.63% 184,282
26-07-23 US$143.21 +0.72% 134,814
26-07-22 US$142.18 -1.22% 143,615
26-07-21 US$143.94 +15.94% 364,767
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
141.77USD
Average target price
229.60USD
Spread / Average Target
+61.95%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PVLA Stock